
																
																	Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials
																
																
																
															Keywords: کیت; Gastrointestinal stromal tumour; KIT; Platelet-derived growth factor receptor alpha; Genotype; Mutational analysis; Imatinib; Dose optimisation